The Patent Finder

TapImmune Inc.

Also on record
Records under this name other than patents TapImmune Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 9 of 9 · Back to TapImmune Inc.

PatentTitleStatus Expires Confidence
US 10,030,252Chimeric Nucleic Acid Molecules with Non-Aug Translation Initiation Sequences and Uses Thereof
Formerly held
Lapsed on the fee record
Ended Jul 24, 2026 · High confidence
Lapsed on the fee recordEnded Jul 24, 2026High confidence
US 9,364,523A chimeric nucleic acid molecule with non-AUG translation initiation sequences
Formerly held
Lapsed on the fee record
Ended Jun 14, 2024 · High confidence
Lapsed on the fee recordEnded Jun 14, 2024High confidence
US 9,988,643Chimeric Nucleic Acid Molecules with Non-Aug Translation Initiation Sequences and Uses Thereof
Formerly held
Lapsed on the fee record
Ended Jun 5, 2022 · High confidence
Lapsed on the fee recordEnded Jun 5, 2022High confidence
US 9,655,956Chimeric nucleic acid molecules with non-AUG translation initiation sequences and uses thereof
Formerly held
Lapsed on the fee record
Ended May 23, 2021 · From the USPTO record
Lapsed on the fee recordEnded May 23, 2021From the USPTO record
US 7,994,146Method of Enhancing an Immune Response
Lapsed on the fee record
Ended Aug 9, 2015 · Medium confidence
Lapsed on the fee recordEnded Aug 9, 2015Medium confidence
US 7,976,850Pox Viridae Treatment
Lapsed on the fee record
Ended Jul 12, 2015 · High confidence
Lapsed on the fee recordEnded Jul 12, 2015High confidence
US 7,378,087Method of Enhancing an Immune Response
Term ended
Ended no later than Sep 23, 2014 · Low confidence
Term endedEnded no later than Sep 23, 2014Low confidence
US 6,361,770Method of enhancing expression of MHC class I molecules bearing endogenous peptides
Lapsed on the fee record
Ended Mar 26, 2014 · From the USPTO record
Lapsed on the fee recordEnded Mar 26, 2014From the USPTO record
US 5,792,604Method of identifying MHC-class I restricted antigens endogenously processed by cellular secretory pathway
Term ended
Term ended no later than Aug 11, 2018 · Low confidence
Term endedTerm ended no later than Aug 11, 2018Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited